SNTI

#4741
Senti Biosciences, Inc. - Common Stock
0.3 4 USD
-0.06%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
0.34
0.34
Year Range
0.34
1.20
Daily Change
-5.56%
Monthly Change
-68.52%
6 month change
-64.29%
Year Change
-64.29%
Previous Close
0.3 6
Open
0.3 4
Low
0.3 4
High
0.3 4
Volume
1
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
Senti Biosciences Holdings, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Senti Biosciences Holdings, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Senti Biosciences Holdings, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Senti Biosciences Holdings, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Senti Biosciences Holdings, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Senti Biosciences Holdings, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Senti Biosciences Holdings, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Senti Biosciences Holdings, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Senti Biosciences Holdings, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Senti Biosciences Holdings, Inc. current report, Q4 FY2025
8-K

Senti Biosciences Holdings, Inc. current report, Q1 FY2025

Senti Biosciences Holdings, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Senti Biosciences, Inc. (SNTI) on February 25, 2025, covering events occurring on February 23, 2025. The filing primarily addresses the appointment of a new Chief Financial Officer and related compensatory arrangements.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.

Material Changes

The primary material change is the appointment of Jay Cross as Chief Financial Officer, effective March 3, 2025. Concurrently, Timothy Lu, M.D., Ph.D., the Chief Executive Officer, served as interim principal financial officer and principal accounting officer from January 31, 2025, until Mr. Cross assumes those roles following the filing of the 2024 Annual Report on Form 10-K.

Compensation and Outlook

Mr. Cross's compensation package includes:

  • Base Salary: $465,000 annually.
  • Target Bonus: 40% of annual base salary.
  • Sign-on Bonus: $50,000, payable if employed for 120 days post-start; repayable if he departs within 14 months (with exceptions).
  • Equity Grant: An option to purchase 174,200 shares of common stock, subject to stockholder approval of "Proposal No. 2" at the March 6, 2025 special meeting. If the proposal fails, the grant reduces to 44,000 shares.
  • Vesting: The option vests over four years (25% on the first anniversary, with the remainder vesting monthly over the next 36 months).

Mr. Cross will also be eligible for a standard Change in Control Agreement 180 days after his start date and will enter into a standard indemnification agreement.

Investor Verification Checklist

  • Verify the outcome of "Proposal No. 2" at the special stockholder meeting on March 6, 2025, as it determines the size of the equity grant (174,200 vs. 44,000 shares).
  • Review the full text of the Offer Letter expected to be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2025.
  • Confirm the exact date Mr. Cross assumes the roles of principal financial officer and principal accounting officer following the 10-K filing.
  • Monitor the company's cash position to assess the impact of the $50,000 sign-on bonus and increased salary obligations.

News